Compare Globus Medical Inc. Class A Common Stock (GMED) vs Honeywell Aerospace Inc. Common Stock (HONA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Honeywell Aerospace Inc. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Honeywell Aerospace Inc. Common Stock trades at $156.54 (market cap $50.14B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 4.9× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Honeywell Aerospace Inc. Common Stock for 0 Days on average.
| GMED | HONA | |
|---|---|---|
Market Cap | $10.25B | $50.14B |
Volume | 1,108,124 | 1,433,364 |
Sector | Health | Industrials |
52-Week High | $96.82 | $269.95 |
52-Week Low | $58.33 | $151.58 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.76B | $64.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Honeywell Aerospace Inc. Common Stock
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →
